MedTrace Logo

MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)

NCT02856698 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2022-06-09

Study results available
· View outcomes & findings →

Summary

Acute pulmonary edema (APE) is a common condition in the emergency room, associated with considerable mortality. The use of intravenous morphine in the treatment of APE remains controversial and Benzodiazepines have been suggested as an alternative for morphine to relieving dyspnoea and anxiety in the patients with APE. The MIdazolan versus MOrphine in APE trial (MIMO) is a multicenter, prospective, open-label, randomized study designed to evaluate the efficacy and safety of morphine in patients with APE.

Conditions

  • Acute Pulmonary Edema

Interventions

DRUG

Midazolam

Dose use according to the product technical sheet

DRUG

Morphine

Dose use according to the product technical sheet

Sponsors & Collaborators

  • Alberto Dominguez-Rodriguez

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-08
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02856698 on ClinicalTrials.gov